Soligenix Inc., a late-stage biopharmaceutical company, has released its financial results for the quarter ended June 30, 2025. The company reported no revenue for this period, consistent with minimal revenue during the same period in 2024. Soligenix's net loss increased to $2.7 million for the quarter, up from a net loss of $1.6 million in the same quarter of the previous year. This increase was primarily attributed to higher operating expenses related to ongoing clinical trials and a decrease in other income due to changes in the fair value of debt in the previous year, with no corresponding change in 2025. Significant operational updates include the successful transfer of the manufacturing process for its synthetic hypericin active ingredient from Europe to the United States, completed under a partnership agreement with Sterling Pharma Solutions. Additionally, on July 31, 2025, Soligenix completed its Phase 2a proof of concept study evaluating SGX945 (dusquetide) in the treatment of Behçet's Disease, achieving the study objective of demonstrating biological efficacy. With approximately $5.1 million in cash as of June 30, 2025, and an additional $1.4 million received via an At-The-Market facility on July 1, 2025, the company aims to strategically allocate resources to achieve upcoming milestones.